Ticagrelor Tablet, Film Coated
Product Images NDC 33342-432

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 33342-432). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ticagrelor-figure-1.jpg (Ticagrelor Figure 1)

A cumulative incidence curve comparing Ticagrelor 90 mg with Clopidogrel over 360 days from the first study drug dose. The graph shows cumulative percentage on the y-axis and days on the x-axis, with Ticagrelor's curve above Clopidogrel's. Patient numbers at risk over time are listed below, with event data and 12-month KM percentages included.*

FDA Label Image

Ticagrelor-figure-10.jpg (Ticagrelor Figure 10)

A cumulative incidence graph displaying the percentage of events over 360 days from randomization, comparing Ticagrelor 90 mg and Clopidogrel. The x-axis shows days from randomization, and the y-axis shows cumulative percentage. Ticagrelor 90 mg is represented by a solid line, Clopidogrel by a dashed line. The risk table below the graph provides patient counts at various time points.*

FDA Label Image

Ticagrelor-figure-11.jpg (Ticagrelor Figure 11)

A forest plot comparing Ticagrelor and Clopidogrel treatment effects across various patient characteristics such as geographic region, ASA dose, treatment approach, PCI timing, diabetes status, prior stroke, age, sex, and race. The plot shows hazard ratios (HR) with 95% confidence intervals and event rates, indicating relative effectiveness and variability by subgroup.*

FDA Label Image

Ticagrelor-figure-12.jpg (Ticagrelor Figure 12)

A forest plot comparing hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel efficacy across different ASA dose ranges and regions (US and Non-US). The chart includes data for ASA doses ≥300 mg, between 100 and 300 mg, and ≤100 mg, illustrating subgroup analyses of the number of events and participants in each group.*

FDA Label Image

Ticagrelor-figure-13.jpg (Ticagrelor Figure 13)

A cumulative percentage line graph depicting event rates over days from randomization for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The graph includes hazard ratios, confidence intervals, and p-values, with numbers at risk listed below the x-axis over time.*

FDA Label Image

Ticagrelor-figure-14.jpg (Ticagrelor Figure 14)

A forest plot showing hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor versus placebo across various patient characteristics and subgroups. The plot includes categories such as age group, sex, race, weight group, BMI, geographic region, history of myocardial infarction, diabetes, coronary artery disease, kidney function, smoking status, and prior treatments, illustrating the relative effect of Ticagrelor compared to placebo on outcomes.*

FDA Label Image

Ticagrelor-figure-15.jpg (Ticagrelor Figure 15)

A line graph depicting cumulative percentage over months from randomization comparing Ticagrelor and Placebo. The solid line represents Ticagrelor, and the dashed line represents Placebo. The graph shows cumulative percentage on the y-axis and months on the x-axis up to 54 months, including numbers at risk for both groups.*

FDA Label Image

Ticagrelor-figure-16.jpg (Ticagrelor Figure 16)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for various patient characteristics between Ticagrelor and placebo groups. The chart shows subgroups such as age, sex, race, body mass index, geographic region, aspirin dose, medical history, and other clinical variables, with Ticagrelor favoring efficacy left of the centerline and placebo favoring right.*

FDA Label Image

Ticagrelor-figure-17.jpg (Ticagrelor Figure 17)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg twice daily (solid line) and placebo (dashed line) over 30 days from randomization. The y-axis shows cumulative percentage, while the x-axis shows days. The graph includes numbers at risk for both groups at various time points and event counts with percentages in the legend.*

FDA Label Image

Ticagrelor-figure-18.jpg (Ticagrelor Figure 18)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus placebo across various patient subgroups. It lists characteristics such as age, sex, race, weight, BMI, geographic region, diagnosis, time metrics, and medical history, showing event counts and percentages for Ticagrelor and placebo groups, with HR values visually represented by squares and lines indicating confidence intervals.*

FDA Label Image

Ticagrelor-figure-2.jpg (Ticagrelor Figure 2)

A bar chart depicting the percentage of patients who had an event following CABG over various days. The x-axis represents days (1, 2, 3, 4, 5, 6, 7, and >=8), while the y-axis shows the percentage, ranging from 0 to 100%. Bars compare two groups labeled T and C for each day. A data table below the graph presents corresponding patient event numbers for both groups at each time point.*

FDA Label Image

Ticagrelor-figure-3.jpg (Ticagrelor Figure 3)

A line graph depicting cumulative percentage over months from randomization for Ticagrelor tablets versus placebo. The graph shows two curves: a solid line for Ticagrelor with events 206/9562 and a dashed line for placebo with events 100/9531, illustrating event percentages up to 54 months. The x-axis represents time in months, and the y-axis represents cumulative percentage (%) with risk numbers provided below the axis.*

FDA Label Image

Ticagrelor-figure-4.jpg (Ticagrelor Figure 4)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg twice daily versus placebo over days from randomization. The solid line represents Ticagrelor with higher cumulative events, and the dashed line represents placebo with fewer events. The graph includes event counts and number at risk for both groups across approximately 30 days.*

FDA Label Image

Ticagrelor-figure-5.jpg (Ticagrelor Figure 5)

A line graph showing IPA (%) induced by 20uM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. Ticagrelor shows a rapid increase and high sustained IPA near 90%, Clopidogrel shows a moderate increase peaking below 50%, and placebo remains near zero throughout the 8-hour period.*

FDA Label Image

Ticagrelor-figure-6.jpg (Ticagrelor Figure 6)

A line graph comparing IPA (%) induced by 20uM ADP over time (days) for Ticagrelor, Clopidogrel, and Placebo groups. Ticagrelor shows a peak with a sharp decline, Clopidogrel rises more moderately and tapers over time, and Placebo remains consistently low. An inset graph shows similar data over a shorter time frame (hours).*

FDA Label Image

Ticagrelor-figure-7.jpg (Ticagrelor Figure 7)

A forest plot showing the mean effect and 90% confidence intervals for Ticagrelor and AR-C124910XX across various intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The horizontal axis represents change relative to reference, with symbols indicating pharmacokinetic parameters Cmax and AUC. Recommendations for all factors indicate no dose adjustment.*

FDA Label Image

Ticagrelor-figure-8.jpg (Ticagrelor Figure 8)

A pharmacokinetic interaction chart illustrating the mean effect and 90% confidence intervals of various interacting drugs on Ticagrelor and AR-C124910XX. The chart plots changes relative to reference for Cmax and AUC, with recommendations on concomitant use or dose adjustments for drugs such as Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl.*

FDA Label Image

Ticagrelor-figure-9.jpg (Ticagrelor Figure 9)

A pharmacokinetic interaction chart showing the mean effect and 90% confidence intervals of ticagrelor on the exposure (Cmax and AUC) of various interacting drugs, such as simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine. The x-axis represents the change relative to the interacting drug alone, indicating recommendations for dose adjustments or monitoring when coadministered with ticagrelor.*

FDA Label Image

Str (Ticagrelor Str)

Chemical structure diagram of the active ingredient Ticagrelor, depicting its molecular arrangement with labeled atoms and bonds, including ring structures and functional groups.*

FDA Label Image

112 (Ticagrelor Tablets 60mg 60s)

Label for Ticagrelor Tablets 60 mg film-coated oral tablets by Macleods Pharmaceuticals Limited. The label includes dosage information, pharmacist dispensing instructions, storage conditions, and manufacturer details. The package contains 60 tablets and bears barcodes and regulatory codes.*

FDA Label Image

113 (Ticagrelor Tablets 90mg 60s)

Ticagrelor Tablets 90 mg film-coated tablet label from Macleods Pharmaceuticals Limited. The label includes dosing information stating each tablet contains 90 mg ticagrelor and storage instructions. It indicates a package size of 60 tablets and provides manufacturer details as Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. Barcode and a designated OPZ area are also present on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.